Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA

January 15, 2018

Responsive image

HOLZKIRCHEN, Germany, Jan. 16, 2018 /PRNewswire/ — Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k) pathway, for…

Category: Precious Metals